AbbVie Inc (ABBV), Perrigo Company plc Ordinary Shares (PRGO), Actavis plc (ACT) and Mallinckrodt PLC (MNK): Cramer’s Favorite Drug Manufacturer Picks in August

AbbVie Inc (NYSE:ABBV), Perrigo Company plc Ordinary Shares (NYSE:PRGO), Actavis plc (NYSE:ACT), Mallinckrodt PLC (NYSE:MNK) are the Cramer’s favorite Drug Manufacturers which have been recommended on Mad Money TV show on August.

For AbbVie Inc (NYSE:ABBV), Cramer said,

“I’m a buyer. It’s a good stock to own.”

AbbVie Inc (NYSE:ABBV) has been working hard to prepare an oral Hepatitis C drug therapies and it is said to have a cure rate of 90% of even higher. The company is leading the race of providing alternative medicine for Hepatitis C against Gilead Sciences, Inc. (NASDAQ:GILD)’s extremely expensive pill, priced at $1000 per pill in the U.S.

In addition to being the most innovative drug company in Forbes’s list, Perrigo Company plc Ordinary Shares (NYSE:PRGO) is a great deal for investors, as said by Cramer. The company has moved to Ireland for maximizing its tax savings by acquiring the Irish drug maker, Elan, and the tax saving tactic is likely to have a positive impact over its shares. Perrigo Company plc Ordinary Shares (NYSE:PRGO) is also one of the three stocks which Cramer’s have big expectations in September.

Actavis plc (NYSE:ACT) is another drug maker in Cramer’s favorite drug manufacturers and he said that the Actavis plc (NYSE:ACT) has a significant room for growth and it is inexpensive. The company is working in collaboration with AstraZeneca plc (ADR) (NYSE:AZN) for ceftazidime-avibactam with some positive results.

For Mallinckrodt PLC (NYSE:MNK), Cramer said that the company has the right formula for growth as well as shareholder profits and the company has maintained growth in the drug industry. Further, Cramer even pointed out that the acquisitions made by the company has allowed it a profitable passage with growth and considering its Dublin base, Mallinckrodt PLC (NYSE:MNK) enjoys a lower tax bracket as well.

This article has been written by Prakash Pandey and edited by Serkan Unal.

Related posts

Top

Warren Buffett's Best Picks

Warren Buffett's these stock picks will crush the market over the next 12 months. Get our report FREE by becoming a member now